CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Palla Pharma Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Palla Pharma Ltd
Twr 4, 727 Collins St
Phone: +61 393010800p:+61 393010800 MELBOURNE, VIC  3008  Australia Fax: +61 393010899f:+61 393010899
Placed into Administration on 12/17/2021
On 12/17/2021, Palla Pharma Ltd was placed into Voluntary Administration.
Craig Shepard and Bryan Webster of KordaMentha were appointed as the Voluntary Administrators of of the Company.
This company is no longer actively traded on any major stock exchange.
Business Summary
Palla Pharma Limited is an Australia-based vertically integrated pharmaceutical company. The Company's primary activities include production and distribution of Narcotic Raw Material (NRM), Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF) for supply to international pharmaceutical markets, and the production and distribution of poppy seed for supply to international culinary markets. The Company operates through two segments: Australia and Norway. Australia segment activities include Narcotic Raw Material and Poppy Seed production and distribution. Norway segment activities include Active Pharmaceutical Ingredient and Finished Dosage production and distribution. The Company has developed a water-based extraction technology, which is used in NRM production. It operates in Victoria and Tasmania; and northern hemisphere operations based in Norway. It sources its raw materials from Australian poppy growers in Tasmania, New South Wales, and Victoria.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202112/31/2020Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer GilesMoss 9/1/2021 9/1/2021
Chief Financial Officer PaulSherman 10/19/2021 10/19/2021
Company Secretary MichaelLicciardo 5/27/2020 5/27/2020

Business Names
Business Name
PAL
TPE

General Information
Outstanding Shares: 161,913,363 (As of 6/30/2021)
Shareholders: 1,758
Stock Exchange: ASX
Fax Number: +61 393010899


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 2, 2024